This is the first double-blind, controlled, randomized study comparing the effect of different
estrogen components in oral contraceptives (OCs) on hemostasis variables. Four groups of …

BACKGROUND: The study was conducted to investigate the effect of a combined oral
contraceptive (COC) containing 30 mcg ethinylestradiol and 2 mg dienogest with two …

We investigated the effects of ethinylestradiol dose (50, 30 and 20 μg) and progestogen type
[desogestrel (DSG), gestodene (GSD), levonorgestrel (LNG) and norgestimate (NGM)] in …

Objectives To determine the effect of two low-dose monophasic oral contraceptives
containing either 2 mg chlormadinone acetate or 150 μg desogestrel on blood clotting and …

The changes in haemostasis during oral contraception are related to the ethinylestradiol
dose present in the formulation taken by the patient. An open, randomized longitudinal study …

We studied 67 healthy women who were randomly allocated to receive third generation
gestodene (Gynera®) or second generation levonorgestrel (Microgynon 30®) combina tion …

Objective To assess the effect on hemostasis parameters of a new combined oral
contraceptive (COC). Study design In this randomized, single centre, open-label, exploratory …

Combined oral contraceptives (OC) are known to increase the risk of venous
thromboembolism. The aim of this randomized, cycle-controlled, cross-over study in 28 …

Objective To determine the effect of oestrogen dose and progestogen type on the
coagulation and fibrinolytic systems of a group of normal healthy women taking three …

Background: A novel estradiol-based combined oral contraceptive (COC) is currently
available in many countries worldwide, including Europe and the US. Based on previous …